| Shengping Li | |
| Title | Professor and Director of the Department of Pancreatobiliary Surgery |
| Profile |
Dr. Shengping Li is currently a professor in the Department of Pancreatobiliary Surgery at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China. He specializes in the treatment of pancreatic and biliary cancers and is a renowned surgical specialist in China. Dr. Li obtained his Doctoral degree in surgery at Sun Yat-sen University of Medical Sciences in 1998 and was a postdoctoral research fellow in The Cancer Center at the University of Michigan, USA in 2003. As the chief expert of pancreatic cancer, Dr. Li has cared for more than 3,000 patients with pancreatobiliary cancer and performs more than 400 surgeries per year, including open, laparoscopic and robot-assited pancreaticoduodenectomy (Whipple), distal pancreatectomy, total pancreaticoduodenectomy, irreversible electroporation (IRE), and radical resection of cholangiocarcinoma. Dr. Li has also designed and conducted a series of clinical trials to test novel drugs and new treatments for pancreatic cancer. His work is mainly focused on multiple disciplinary treatment of pancreatobiliary cancer and its effects on the tumor immune microenvironment, specifically, tumorigenesis, development and prognosis. He has established an international reputation in pancreatic and biliary cancers, and served as a steering committee member in several academic organizations. He has published more than 90 peer-reviewed papers, including papers in renowned journals such as Hepatology, the Journal of Hepatology, Cancer Research, Cancer Letters, Clinical translational medicine, Oncoimmunology, and Frontiers in Oncology.
|
| lishp@sysucc.org.cn | |
| Phone | |
| Research Interest(s) |
Multiple disciplinary treatment, especially surgical treatment of pancreatobiliary cancer, the treatment of locally advanced pancreatic cancer with irreversible electroporation and its immune changes in the tumor microenvironment, the design and conduct of clinical trials on pancreatobiliary cancer. |
| Education |
M.D. School of Medicine, Hengyang medical college, Nanhua University, China, 1981-1986. |
| Publications |
Selected publications 1. The T cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. He C#, Huang X#, Zhang Y#, Cai Z, Lin X, Li S*. Clinical and Translational Medicine. 2020 Jun;10(2):e39. 2. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Huang X#, He C#, Hua X#, Kan A, Mao Y, Sun S, Duan F, Wang J, Huang P, Li S*. Clinical and Translational Medicine. 2020 Jun;10(2):e41. 3. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Sun S#, Liu Y#, He C#, Hu W, Liu W, Huang X, Wu J, Xie F, Chen C, Wang J, Lin Y, Zhu W, Yan G, Cai J*, Li S*. Cancer Letters. 2021 Apr 1;502:9-24. 4. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer, He C#; Sun S#; Zhang Y#; Xie F; Li S*; OncoImmunology, 2021, 10(1): 1-12. 5. Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. He C#, Huang X#, Zhang Y#, Cai Z, Lin X, Li S*. Frontiers in Oncology. 2020 Jan 22;10:6. 6. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. He C#, Sun S#, Zhang Y#, Lin X, Li S*. Frontiers in Oncology. 2020 Sep 3;10:1564. 7. The impact of different metastatic patterns on survival in patients with pancreatic cancer. He C#, Huang X#, Zhang Y#, Lin X, Li S*. Pancreatology. 2021 Jan 27:S1424-3903(21)00038-7. 8. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. He C#, Wang J#, Zhang Y#, Lin X, Li S*. Pancreatology. 2020 Apr;20(3):477-484. 9. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Xu L, Wang J, Kim Y, Shuang Z, Zhang Y, Lao X, Li Y, Chen M, Pawlik T, Xia J, Li S*, Lau W. Oncoimmunology. 2016 Mar;5(3):e1083671. 10. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, Lao XM, Zheng L, Li S*. Cancer Letters. 2014 Nov 28;354(2):320-8. Updated March 2021 by International Office, Sun Yat-sen University Cancer Center
|
| Lao Xiangming | |
| Title | Deputy Director and Chief physician |
| Profile |
Prof. Lao specializes in surgical treatment of hepatobiliary and pancreas tumor, treatment and research of HBV-related hepatocellular carcinoma, hepatitis and liver cirrhosis and cancer immunization. |
| Phone | |
| Research Interest(s) |
Diagnosis and treatment of hepatocellular carcinoma, hepatitis and liver cirrhosis.
|
| Education |
1994-1999: Studied at Department of Clinical Medicine, former Sun Yat-sen University of Medical Sciences 1999-2001: Studied as a master's degree student at former Sun Yat-sen University of Medical Sciences 2004-2007: Studied as a doctoral student 2009-2010: Worked and conducted researches at Department of Oncology Surgery University of Michigan
|
| Publications |
1) Primary carcinosarcoma of the liver: Clinicopathologic Features of 5 Cases and a Review of the Literature. American Journal of Surgical Pathology, 2007,31(6):817-826. 2) Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases. Hepato-Gastroenterology, 2006;53 (67):128-132. 3) A gastrointestinal stromal tumor of the jejunum associated with intrahepatic cholangiocarcinoma and pulmonary hamartoma: a case report. Acta Oncol. 2009 Feb 25:1-4. Updated by International Office, Sun Yat-sen University Cancer Center |
| Cui Bokang | |
| Title | Associate chief physician |
| Profile |
Dr. Bokang Cui received his medical degree from Norman Bethune University(present Norman Bethune Medical College of Jilin University),Changchun,Jilin Province, PR China in 1997. From 1997 to 2001, He got his resident training in General Surgery Department of Hainan Bianfang Hospital, Haikou, PR China. Dr. Cui received his Master degree of Science and PhD in Oncology from SunYat-sen University of Medical Sciences in 2004 and 2013. Since then he pursued a surgical fellowship in hepatobiliary oncology and held a position of attending surgeon and associate professor of surgical oncology in Department of Hepatobiliary Oncology in this cancer center in 2004 and 2012, respectively.
|
| cuibk@sysucc.org.cn | |
| Phone | |
| Research Interest(s) |
Liver cancer multi-modality treatment including: Hepatectomy, Transcatheter Hepatic artery Chemoembolization(TACE), Lapascopic hepatectomy. Biliary tract cancer, carcinoma of gallbladder, pancreatic cancer surgical treatment. Translational Medical research for hepatocellular carcinoma.
|
| Education |
09/1992-07/1997: Graduated from the third Clinical Department of Former Norman Bethune University of Medical Science(currently Norman Bethune Health Science Center of Jilin University) and was conferred upon a bachelor's degree 09/2011-07/2004: Graduated from Sun Yat-sen University and was conferred upon the degree of Master of Clinical Medicine 09/2006-12/2009: Studied in oncology as a doctoral student at Sun Yat-sen University |
| Publications |
Updated by International Office, Sun Yat-sen University Cancer Center |
Copyright：Sun Yat-sen University Cancer Center Designed by Wanhu.
